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In the transformation of fibroblasts by defective sarcoma viruses, the role of the helper 
virus has usually been interpreted as the provision of virion proteins. These may include 
the  internal  structural  components,  the  external  glycoproteins,  and/or  the  reverse 
transcriptase (1-4). The ease with which nonproducer, transformed cells can be isolated 
(5, 6) has suggested that the helper genome plays no role in transformation by defective 
sarcoma  viruses  and  in  certain  cases  direct  examination  of transformed  cells  has 
confirmed the  absence of certain helper nucleic acid sequences  (7,  8).  Thus,  we  view 
fibroblast transformation solely as a  consequence of the action of a  gene or genes of the 
defective virus, a view which is supported by the apparent independence of the avian src 
gene  from the rest of the nondefective Rous  sarcoma virus genome  (9,  t0).  With this 
background we have been analyzing the helper specificity for transformation of lympho- 
cytes by the Abelson murine leukemia virus (A-MuLV).' 
A-MuLV, originally isolated from a  tumor arising in a  prednisolone-treated BALB/c 
mouse inoculated with Moloney murine leukemia virus (M-MuLV), induces a  thymus- 
independent lymphoma 3-5 wk postinoculation (11).  A-MuLV resembles rapidly trans- 
forming murine sarcoma viruses in its mode of replication on fibroblast cell lines. The 
virus stocks from A-MuLV-induced tumors contain a  defective virus which transforms 
some  fibrobtasts  and  an  oncogenic  thymic  lymphoma  helper  virus,  M-MuLV.  The 
transforming component of A-MuLV can be obtained free of replicating helper virus by 
isolating nonproducer fibroblast cell lines (12).  Several of these cell lines lack significant 
sequences of the helper virus genome (7, 8). 
A-MuLV  is unique  in that  it also transforms  lymphoid cells in vitro  (13).  A 
quantitative  semisolid culture system which monitors the frequency of transfor- 
mation has been developed (14). To analyze the role of helper virus in A-MuLV- 
induced transformation,  we tested the oncogenic activity and the transforming 
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Virus stock  Abbreviation used 
Moloney murine leukemia virus,  clone 1 (reference  18) 
Moloney murine leukemia virus,  clone 2 
Friend murine leukemia virus (N-tropic),  clone 13 
Friend murine leukemia virus (B-tropic),  clone 10 
BALB/c endogenous virus WN1802N-C135  (references  19 and 20) 
Gross murine leukemia virus 
M-MuLV-1 
M-MuLV-2 
F-MuLV-N 
F-MuLV-B 
E-MuLV 
G-MuLV 
ability of A-MuLV stocks  prepared with several different helper viruses.  For 
fibroblasts,  all  of the  murine  retroviruses tested  were  equivalently effective 
helpers and A-MuLV stocks  prepared with helpers that  are highly oncogenic 
were  found  to  be  highly  oncogenic in  vivo  and  to  transform  lymphoid cells 
efficiently. We were  surprised,  however,  to  find that  A-MuLV prepared  with 
helpers that  are  weakly oncogenic alone is very inefficient as a  transforming 
agent either in vivo and in vitro. This result suggests that the helper virus may 
play  a  more  active  role  in  lymphoid cell  transformation  than  in  fibroblast 
transformation. 
Materials  and  Methods 
Cell Cultures.  Most fibroblast cell cultures were maintained in Dulbecco's modified Eagle's 
medium (Grand Island Biological Co., Grand Island, N. Y.) supplemented with 10% calf serum 
(Microbiological Associates,  Walkersville, Md.) (DME-CS). JLS-V9  and CCL64 mink lung cells 
were maintained in DME supplemented with 10% heat inactivated (at 56°C for 30 rain) fetal calf 
serum (Microbiological Associates)  (DME-IFS).  5H cells,  an A-MuLV-transformed nonproducer 
fibroblast clone,  were derived by infecting JLS-V9 cells at a multiplicity of infection (moi) of 3 
focus-forming  units (FFU) and 2 plaque-forming units (PFU) with A-MuLV(M-MuLV-1) (see 
Table I for a description of the helper viruses used). After a 1.5-h adsorption period, the cells were 
washed two times with phosphate-buffered saline (PBS) (200 rag/liter KC1, 200 rag/liter KH~PO,, 
100 mg/liter MgCI~.  6H,O, 8,000 rag/liter NaC1, 1,150 mg/liter Na~HPO4.2I-I~O), trypsinized for 7 
min at 37°C, and plated in microtiter wells at a concentration of 0.33 cells/well.  Transformed 
clones were isolated 14 days later and screened for virus production by using infectivity and 
reverse transcriptase assays. 5H cells are morphologically  transformed but supernates from these 
cells contain no detectable infectious virus or reverse transcriptase. The cells contain the A- 
MuLV genomes as demonstrated by rescue experiments with M-MuLV-2. 
Lymphoid Cell Lines.  A-MuLV-transformed lymphoid cell  lines were derived by removing 
single foci from agarose transformation plates with a Pasteur pipette. The cells were transferred 
to 16-ram plastic wells (Coming Glass Works,  Corning, N. Y.), suspended in 1 ml of RPMI-1640 
(Grand Island Biological Co.), supplemented with 20% heat inactivated fetal calf serum and 50 
~M 2-mercaptoethanol (Eastman Kodak Co., Rochester,  N. Y.) (RPMI medium). Cultures were 
observed daily for  growth and maintained at densities of 5  ×  105-1 ×  10  e cells/ml until the 
cultures grew vigorously, doubling  every 12 h. The length of this adaptation period usually varied 
from 3 to 4 days to 1-2 wk. Once established, cells were paseaged  at a 1:100 split ratio when they 
reached a density of 2.5-3.5  × 108 celts/ml, about every 3rd day. 
BR48 is an A-MuLV-transformed lymphoid nonproducer cell line derived from A-MuLV(M- 
MuLV-1)-infected C57BR/cdJ  (Fv-1  ~n) bone marrow cells.  2M is another A-MuLV-transformed 
nonproducer cell line derived from A-MuLV(M-MuLV-2) infected BALB/c (Fv-1  b~b) bone marrow 
cells.  Both  of these  cell lines contain the  A-MuLV  genome as  demonstrated by recovery  of 
oncogenic, transforming virus after M-MuLV-2 superinfection. 
L691 cells,  a gift of Dr.  Paul Arnstein, California State Department of Health, were derived 
from a radiation-induced  thymoma in a C57L mouse (15). These cells express markers commonly 
associated  with T-cell tumors such as Thy-1, TL, and Lyt-4 antigens, and the enzyme terminal 1128  ABELSON  VIRUS 
deoxynucleotidyl  transferase  (16,  17; A.  Silverstone et  al.,  unpublished results).  No  infectious 
ecotropie  virus has been isolated  from the cells,  but xenotropic  virus  can be recovered by cocul- 
tivation  of  L691  cells  with  CCI~4 mink lung  cells  or  other  non-murine  cell  lines  (15;  N. Rosenberg 
and D.  Baltimore, unpublished results). 
Virus  Stocks.  M-MuLV-I,  M-MuLV-2,  Friend-MuLV(F-MuLV)-N,  Gross-MuLV(G-MuLV), 
G-MuLV,I, and E-MuLV were all grown as N/HI3T3 carrier  cell  cultures  (Table I). F-MuLV-B 
was maintained as  a BALB/3T3 carrier  culture.  M-MuLV-I was  originally  isolated  from  JLS-Vll 
cells  by end point  dilution  as  previously  described  (18).  M-MuLV-2 was isolated  from M-MuLV-I 
by cloning NIHI3T3 cells  a~er adsorption of  virus at  low multiplicity.  E-MuLV  was isolated  by 
end point dilution  of  WN1802N  (19)  as previously described (20).  G-MuLV, originally  obtained 
from Dr. Nancy Hopkins, M.I.T.,  was cloned  by  infecting  NIH/3T3 cells  at  a moi  of  0.3  PFU. After 
a 1.5-h  adsorption  period,  the infected  ceils  were trypsinized  and plated in microtiter  plates  at a 
concentration of  0.3 cells/well.  10 days later,  all wells  containing cells  were assayed for virus 
production  by the XC plaque  assay (21).  2  of  51 clones  released  infectious  virus,  and one of  these, 
G-MuLV-I, was selected  for  use in experiments. Cloned F-MuLV stocks  originally  obtained from 
Dr. Robert  Eckner, Boston  University School of  Medicine, Boston, Mass. were a gift  of  Dr. Alfred 
Bothwell, M.LT. F-MuLV-N and F-MuLV-B were isolated  by low moi and cloning of  SC-I cells. 
C57BI/KaB (22),  a clone  of  flbrotropic  C57BI/6 virus,  was a gift  of  Doctors Henry Kaplan and 
Alain Decl~ve, Stanford University,  Stanford,  Calif. 
A-MuLV stocks  were prepared  by superinfecting  mass cultures  of  nonproducer flbroblast  cells 
with  helper  virus.  After  a 2-h  adsorption period,  the  cells  were maintained  at  high densities  with 
frequent medium changes for 1.5-2  wk So allow virus spread. Both helper virus  and A-MuLV 
stocks  were prepared from  24-h  harvests of  exponentially  growing  cultures.  The virus  supernates 
were  centrifuged  for  15  rain  at  low  speed,  filtered  through  a  0.45-ft  filter  (Millipore  Corp.,  Bedford, 
Mass.),  and frozen  at -70°C for  subsequent use. 
For quantitative rescue experiments with lymphoid nonproducer cells, 2 ×  10  ~ cells  were 
resuspended directly  in i ml of the helper virus preparations supplemented with 8 ~glml 
polybrene IAldrich  Chemical Co., Milwaukee, Win.).  After s 1.5-h  adsorption period,  the cells 
were collected  by low speed centrifugation,  washed once with i0 ml of  PBS, and treated with 
0.25% trypsin,  0.2% EDTA  for 7-10 rain  at .~7°C.  Trypsin-EDTA was removed by low speed 
centrifugation  and the cells  were plated in 4 ml of  RPMI medium. Subsequently, culture fluids 
were collected  for  virus  assay at  24-h  intervals.  The  cells  were  collected  and  replated  at  the  initial 
cell  density (5 × 1& cellslml)  in  fresh  medium for  the next collection  interval. 
Virus Ass,,ys.  Helper  viruses  were  assayed  on  NIH/3T3  and BALB/3T3  cells  by using the 
standard XC assay or by mouse S+L- assay with FG-1I) ceils (23).  FG-10 assays were carried out 
by plating I  ×  l0  s cells in 60-ram plastic dishes. 24 h  later, the cells were infected with 0.5 ml of 
virus. After a 2-h adsorption period in the presence of 8 #~gjml polybrene, the cells were fed 4 ml of 
DME-CS  and incubated. The S+L- plaques were visualized  by hematoxylin staining 5 days 
postinfection.  The titers  obtained with  the  XC and  FG-10 assays were equivalent  for  all  the virus 
stocks (data  not shown). 
Fibroblast  transformation assays were used to  standardize  the  FFU in  A-MuLV stocks.  Either 
1 ×  10  ~ NIHf3T3 or BALB/3T3 cells, plated in 60-ram dishes 24 h previously, were infected with 
0.5-ml portions of virus. After a  2-h adsorption period in the presence of 8/ag/ml polybrene, the 
plates were fed fresh DME-CS,  and incubated.  Medium was changed 5 and 10 days postinfection 
and  foci  were  scored  in  live  cultures  by  using  low  power  magnification  (×  100)  st  15  days 
postinfection (12). The amount of helper virus present in A-MuLV stocks was determined by using 
SC or S+L- assays. 
All  helper  virus  and  A-MuLV  preparations  were  screened  for  the  ability  to  replicate  on 
xenogeneic cells.  For  this  assay,  CCL64 mink lung  cells,  plated  24  h previously  at  I × I0  ~  cellsl60 
mm  dish,  were infected  with  0.5 ml of  undiluted virus  stock  containing 8 ~g[ml polybrene. After 
a 2-h adsorption period,  the cell~  were fed fresh  DME-IFS and incubated. Cells  were psssaged 
twice weekly and screened for  the presence of virus  by using a standard reverse tra~ascriptase 
assay 6 wk postinfection. 
Bone Marrow Transformation.  Transformation of mouse bone marrow cells was carried out as 
previously described (14).  Briefly, 2  ×  10  s nucleated cells were plated in 35-ram dishes in 1 ml of 
RPMI medium.  1 ml of virus suspension was added to the dishes and the plates were incubated. 
I/2  ml of  fresh  RPMI medium was added to  the cultures  6 and 12 days postinfection.  Transforma- 
tion  was recognized by rapid proliferation  of  immature lymphoid cells  in the culture  fluid. NAOMI  ROSENBERG  AND  DAVID  BALTIMORE  1129 
Mice.  The mice used for most experiments were supplied by our breeding colony at  M.I.T. 
NIH/Swiss  mice  were  originally  obtained  from  the  Division  of Research  Services,  National 
Institutes of Health,  Bethesda,  Md.  BALB/cAN  mice were  obtained from  Dr.  Herman  Eisen, 
M.I.T. CD-1/Swiss mice were purchased from Charles River Breeding Laboratories, Wilmington, 
Mass.  For certain experiments, C57BR/cdJ mice were purchased from The Jackson Laboratory, 
Bar Harbor, Maine. 
For induction of leukemia all animals were inoculated intraperitoneally with 0.1 ml of 0.45 ~m 
of filtered virus suspension at less than 48 h of age. Animals were observed weekly for cachexia, 
anemia, lymphadenopathy, or splenomegaly.  Mice inoculated with M-MuLV clones and F-MuLV 
clones remaining disease free were sacrificed 6 mo pestinoculation.  Animals inoculated with E- 
MuLV and G-MuLV were held for 15 too. Mice inoculated with all A-MuLV stocks were observed 
for 3 mo. Gross pathologic findings were noted for all animals either when illness was noted or at 
the termination of the experiments. Spleen, thymus, lymph node, liver, and any other abnormal 
tissues from  representative animals were  also  fixed  and  processed  for histologic examination 
according to routine procedures. 
For studies on recovery of A-MuLV from mice, several NIH/Swiss litters were randomly mixed 
and  then  redivided  for  virus  inoculation.  Each  mouse  received  equivalent doses  of either A- 
MuLV(M-MuLV-1) or A-MuLV(G-MuLV). Animals were sacrificed by cervical fracture 4,  10,  15, 
and 21 days postinfection (and, in the case of A-MuLV(M-MuLV-1), when disease was evident). 
The animals were examined for evidence of disease and spleen, thymus, femur,  and tibia were 
removed  and frozen immediately on  dry  ice.  Virus extracts,  prepared in  RPMI containing no 
serum,  were  made by using a  dounce homogenizer or  a  mortar and pestle.  The extracts were 
centrifuged twice at 2,500 rpm for 30 min and filtered through a  0.45-~m Millipere filter before 
infectivity studies. Protein concentration in the extracts was determined by the standard Lowry 
et al. procedure (24). 
Reverse Transcriptase  Assays.  24-h supernates from exponentially growing cell cultures were 
clarified by low speed centrifugation.  The supernates were then centrifuged at 100,000 g  for 45 
min at 4°C.  Pellets were resuspended in 0.5 ml of 0.01 M Tris-HCl (pH 7,5) and sonicated for 40 s 
in  a  Raytheon  sonic  oscillator,  Raytheon  Co.,  Portsmouth,  R.I.  A  50-~1  portion  of the  virus 
suspension was assayed for exogenous reverse transcriptase activity in 0.1 ml reaction mixture 
containing 0.05 M Tris-HC1 buffer (pH 8.3), 0.06 M NaC1, 6 mM MnC12, 0.02 M dithiothreitol, 1 
~g pely(rA) (Miles Laboratories, Inc., Kankakee, Ill.), 0.5 pg oligo(dT) (Collaborative Research, 
Inc.,  Waltham,  Mass.),  0.05%  Nonidet  P-40  (Gallard  Schlesinger Chemical  Mfg.  Corp.,  Carle 
Place, N.Y.),  and 10 -s M  [3H]dTTP (52 Ci/mmol) (New England Nuclear, Boston, Mass.). 
Results 
The  tropism  of the  helper  viruses  described  in  Table  I  was  determined  by 
using the XC plaque assay method (21) on NIH/3T3 and BALB/3T3 cells (Table 
II). Both cloned stocks of M-MuLV produced equivalent numbers of large, clear 
plaques  on the  two cell  lines  and  were  therefore  NB-tropic  (25).  The  two  F- 
MuLVs were of opposite tropism, one preferring NIH/3T3 cells (F-MuLV-N) and 
the other BALB/3T3 cells (F-MuLV-B). The G-MuLV stocks and E-MuLV clone 
were  N-tropic,  producing  small,  clear  XC  plaques  preferentially  on NIH/3T3 
cells.  All  of  the  viruses  replicated  to  high  titer  in  fibroblast  cells  of  the 
appropriate Fv-1 genotype.  None of the virus stocks had an amphotropic host 
range as determined by their inability to establish an infection in mink cells. 
The oncogenicity of helper virus preparations was determined by inoculating 
newborn mice of proper Fv-1 genotype with 0.45 ~m filtered virus stocks (Table 
III). 2 Mice  were  sacrificed  when  signs  of disease  were  evident  and  gross and 
histologic  examinations  were  conducted.  Both  M-MuLV-1  and  M-MuLV-2 
induced disease in 96-100%  of both Swiss and BALB/c  mice after a  2.5-3.5-mo 
latent  period.  Hepatosplenomegaly  and  large  mesenteric  lymph  node tumors 
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TABLE  II 
Properties of Helper Viruses 
Virus stock 
Titer 
NIH  BALB 
Growth on mink 
lung cells 
M-MuLV-1  2  x  106  1  x  106 
M-MuLV-2  2  x  l0  s  1  ×  106 
F-MuLV-N  4  x  105  1  x  102 
F-MuLV-B  <10  1  x  l0  s 
E-MuLV  1  x  104  1  ×  102 
G-MuLV  3  ×  105  1  x  102 
G-MuLV-1  2  ×  105  8  x  102 
0.5-ml portions of filtered virus dilutions were exposed to NIH/3T3 or BALB/ 
3T3 cells plated 24 h  earlier at densities of 5  x  104 cells or 7.5  x  104 cells/60 
mm  dish.  After a  2-h virus adsorption  period,  cells were  fed fresh DME-CS 
and incubated.  3  days later the plates were irradiated  with ultraviolet light 
and  1  x  106  XC  cells were  added.  Plaques  were  visualized by hematoxylin 
staining. 
Growth of virus stocks on mink lung cells was monitored by reverse transcrip- 
tase assay 6 wk postinfection. 
were prominent features of the disease and thymomas were noted in about 50% 
of the animals. Histologic examination of tumor tissue showed that the tumors 
were  composed  of  lymphoblasts.  M-MuLV-2  titrations  in  NIH/Swiss  mice 
indicated that doses less than 6  x  103 were effective in disease induction (data 
not shown). 
F-MuLV-B and F-MuLV-N were also oncogenic. Both viruses induced dis- 
eases confined to the spleen and liver. Mesenteric and peripheral lymph nodes 
and the thymus of inoculated mice were normal. Histologic examination of the 
diseased  tissues  showed  the  F-MuLV-B-induced tumors  to  be  composed  of 
lymphoblasts,  morphologically indistinguishable from the  cells  in  M-MuLV- 
induced tumors. As with M-MuLV, F-MuLV-B induced a  disease after a  2.5- 
3.5-mo latent period.  F-MuLV-N induced disease after a  short, 5-6 wk, latent 
period.  The types of cells in F-MuLV-N-induced tumors have not been fully 
characterized.  The virus stocks did induce disease in adult mice but did not 
induce spleen foci characteristic of Friend virus complex with the standard 9 
day focus assay (26) (data not shown). 
Neither E-MuLV nor G-MuLV induced tumors in NIH/Swiss mice. Inoculated 
animals were observed for 15 mo and no gross or histologic evidence of tumors 
was noted. 
Characterization  of Abelson  Stocks.  Two  A-MuLV-transformed  nonpro- 
ducer fibroblast cell lines were used to prepare A-MuLV stocks with the various 
helpers.  ANN-1  cells  (12), derived from NIH/3T3 cells,  were used to prepare 
virus stocks with N- and NB-tropic helpers and 5H cells, derived from BALB/c 
JLS-V9  cells  (27), were  used to prepare  virus stocks with B-  and  NB-tropic 
helpers.  The  focus-forming component of all  virus  stocks was  monitored by 
transformation of NIH/3T3 or BALB/3T3 cells and the titers are represented as 
FFU. Helper virus titers were determined by using XC or S+L- plaque assays 
and are  represented  as  PFU.  All  A-MuLV stocks transformed fibroblasts of NAOMI  ROSENBERG  AND  DAVID BALTIMORE 
TABLB III 
Oncogenicity of Helper Viruses 
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Titer inocu-  Disease fre- 
Virus stock  Mouse strain 
lated  (PFU)  quency 
Latent period 
Mean  Range 
days 
M-MuLV-1  1  x  104  N  15/15  102  78-118 
1  x  104  B  30/31  83  77-91 
M-MuLV-2  7  x  103  N  6/6  92  72-109 
3  x  I0  ~  B  6/6  109  94-128 
F-MuLV-N  I  ×  l04  N  5/6  37  34-39 
E-MuLV  3  ×  104  N  0/11  -  - 
G-MuLV  3  x  104  N  0/11  -  - 
Neonatal mice were inoculated intraperitoneally with filtered virus stocks and observed for signs 
of disease.  Animals inoculated with E-MuLV and G-MuLV were observed for 15 mo. The mouse 
strains used were either CD-1 or NIH/Swiss (N) and BALB/c (B). CD-1 and NIH/Swiss mice are 
equally susceptible to these lymphoma viruses. 
appropriate  Fv-1  genotype efficiently and  reflected the  tropism  of the  helper 
virus (Table IV). The proportion of helper virus in virus stocks varied with the 
preparation  but  most  of the  virus  stocks had  PFU/FFU ratios  of 1-5.  Virus 
stocks prepared  with  M-MuLV-1  and  ANN-1  cells  and  one  ANN-l-grown  F- 
MuLV-N stock contained virus that could replicate in mink lung cells. Occasion- 
ally, preparations  made with 5H cells contained virus that could replicate on 
mink cells after long-term infection (Table IV). Xenotropic virus probably arises 
as a  low level contaminant  from the rescued A-MuLV nonproducer cell lines. 
Most transformed  lymphoid cell lines  isolated  with these virus stocks do not 
release virus which grows on mink lung cells (data not shown). 
To determine the relationship between FFU and Abelson disease induction, 
an  in  vivo  A-MuLV titration  was  performed  initially  by using  A-MuLV(M- 
MuLV-2) and NIH/Swiss mice.  Mice were sacrificed when cachexia, lymphade- 
nopathy,  paralysis  of hind  limbs,  or  meningeal  tumors  evident  grossly as  a 
bulging of cranial bones were noted.  Animals with lymphosarcomas involving 
bone marrow and peripheral lymph nodes with slight splenomegaly and normal 
thymus and mesenteric lymph nodes were scored as positive for Abelson disease. 
An inoculum of 10  ~ FFU induced disease in more than 50% of the test animals 
while only 1 of 11 mice inoculated with 5 ×  102 FFU developed Abelson disease 
(Table V). 
A-MuLV prepared with the various helper viruses was then inoculated into 
newborn mice at doses expected to give a  high disease frequency based on the 
A-MuLV(M-MuLV-2) titration.  A-MuLV stocks prepared with both clones of M- 
MuLV induced disease efficiently in NIH/Swiss and BALB/c mice after a  3-5- 
wk latent period (Table VI). Typical Abelson lymphosarcomas, characterized by 
large tumors of peripheral lymph nodes, spine, and skull with slight splenomeg- 
aly and normal thymus, were found in these animals. Histologically, the tumors 
were composed of immature lymphoid cells. Disease after A-MuLV(F-MuLV-B) 
inoculation  was  similar  to  the  syndrome  observed when  A-MuLV(M-MuLV) 
clones  were  used.  The  A-MuLV(F-MuLV-B)  stocks  were  more  efficient  in 
BALB/c than NIH/Swiss mice. 1132  ABELSON  VIRUS 
TABLe. IV 
Properties of A-MuL V Stocks 
Virus stock 
PFU Titer  FFU Titer 
NIH  BALB  NIH  BALB 
Growth on 
mink lung 
cells 
ANN-I(M-MuLV-I)  1 x  10  6  7 x  10  5  1 x  10  6  7 x  10  5  + 
ANN-I(M-MuLV-2)  1 x  10  6  ND*  5  x  10  5  5  x  10  5  ND 
ANN-I(F-MuLV-N)  2  x  10  5  4  x  i0  '  7 x  10  5  <I0  +/- 
ANN-I(E-MuLV)  2  x  10  4  3  x  I0  ~  4  x  10  4  I  x  10  2  - 
ANN-I(G-MuLV)  8 x  10  4  3  x  10  2  1 x  10  ~  8  x  I0'  - 
5H(M-MuLV-2)  3  x  l0  s  2  x  i0  ~  9  x  10  4  4  x  10  4  + 
5H(F-MuLV-B)  <10  1 x  I0  ~  <I0  2  ×  10  5  +/- 
0.5-ml portions of filtered virus dilutions were exposed to NIH/3T3 or BALB/3T3 cells for assay 
by the standard XC plaque test or the A-MuLV fibroblast focus assay. For the XC test, XC cells 
were  added to  monolayers irradiated  with ultraviolet light 3 days postinfection and plaques 
were scored 3 days later. A-MuLV transformed foci were scored 15 days postinfection. Growth of 
virus on mink lung cells was monitored by reverse transcriptase assay 6 wk postinfection. The 
A-MuLV stocks are described by the nonproducer cell from which they were derived and,  in 
parenthesis, the helper virus used for rescue. 
* ND, not done. 
NIH/Swiss mice inoculated with A-MuLV(F-MuLV-N) also developed typical 
Abelson disease  (Table  VI).  However, in  all of the mice inoculated  with this 
virus stock, hepatosplenomegaly was a  prominent feature of the disease.  This 
type of pathology is very uncommon in Abelson disease and probably reflects 
the action of the F-MuLV-N helper virus in the preparation.  The overlapping 
latent  period for F-MuLV-N disease and Abelson disease makes it difficult to 
assess which cells have responded to which virus.  Skull, spine,  and peripheral 
lymph node tumors,  characteristic  of Abelson disease,  and  never noted in F- 
MuLV-N injected mice,  were present  in  about 40%  of the animals.  The high 
titer of helper virus in the particular A-MuLV(F-MuLV-N) preparation used in 
these animal experiments may account for the high proportion of animals with 
hepatosplenomegaly. 
Mice  inoculated  with  A-MuLV(G-MuLV)  did  not  develop  any  detectable 
disease during a 3-4-mo observation period. To determine if A-MuLV(G-MuLV) 
replicates in inoculated animals, lymphoid tissues from NIH/Swiss mice injected 
with this virus stock were extracted and examined for virus by using the S+L- 
assay and the NIH/3T3 focus assay (Fig.  1). Tissues from mice inoculated with 
an  equivalent  amount  of A-MuLV(M-MuLV-1)  served as controls.  The  virus 
dose used, 2  ×  104 FFU, induced disease in 100% of the A-MuLV(M-MuLV-1) 
inoculated mice. A-MuLV(M-MuLV-1) replicated well in the mice and as early 
as 4 days postinjection both components of A-MuLV could be detected in bones 
of the animals. Helper virus was also recovered from spleen and thymus. As the 
incubation period increased, the titer of A-MuLV increased. The higher titer of 
A-MuLV in thymus tissue observed in the tumored mice probably arises from 
large parathymic lymph node tumors in these animals.  No virus was recovered 
from bone, spleen, or thymus of A-MuLV(G-MuLV) injected mice. Litter mates 
of the A-MuLV(G-MuLV) mice sacrificed in these experiments are healthy 5 mo 
postinoculation. NAOMI  ROSENBERG  AND  DAVID  BALTIMORE 
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Titer inoculated  Disease fre-  Latent period 
PFU  FFU  quency  Mean  Range 
days 
1.5  x  l0  s  5  x  104  8/8  24  21-28 
1.5  x  104  5  ×  l0  s  6/7  33  29-40 
3  ×  10  s  1  x  l0  s  3/5  75  71-78 
1.5  x  l0  s  5  x  10 z  1/11  -  78 
Neonatal mice were inoculated intraperitoneally with 0.1 ml of filtered virus stock. 
Animals were sacrificed when disease was evident.  Animals were observed for at 
least 5 mo. 
TABLE  VI 
Oncogenicity of A-MuL V Stocks 
Titer inoculated  Mouse  Disease  Latent period 
Virus stocks 
PFU  FFU  strain  frequency  Mean  Range 
days 
ANN-I(M-MuLV-1)  1  ×  l0  s  2  x  104  N  4/4  30  28-30 
ND*  2  x  104  B  7/7  19  18-20 
ANN-I(M-MuLV-2)  1  x  104  5  ×  103  N  8/8  37  29-43 
B  ND  -  - 
ANN-I(F-MuLV-N)  2  ×  104  4  ×  103  N  11/11  41  38-55 
B  ND  -  - 
5H(M-MuLV-2)  3  ×  104  6  x  103  N  5/9  54  28-87 
B  5/5  28  23-30 
5H(F-MuLV-B)  1  x  10  ~  3  ×  104  N  1/6  30  30 
B  5/6  31  24-47 
ANN-I(G-MuLV)  8  x  103  1  ×  104  N  0/14  -  - 
B  ND  -  - 
Neonatal  mice were inoculated  intraperitoneally with 0.1  ml of filtered virus stock.  Animals 
were sacrificed  when disease  was evident.  Animals were observed for at least  3  too.  Mouse 
strains used were NIH/Swiss (N) and BALB/c  (B).  The A-MuLV stocks are described by the 
nonproducer cell from which they were derived and, in parentheses, the helper virus used for 
rescue. 
* ND, not done. 
Transformation  of Bone Marrow  Cells.  To determine the effect of helper 
viruses on the ability of A-MuLV stocks to transform hematopoietic cells in 
vitro, bone marrow cells from 4- to 6-wk old mice were infected and plated in a 
quantitative agarose transformation assay. Macroscopic foci of lymphoid cells 
were counted 12 days postinfection (Table VII). The transformation frequency 
obtained with different virus preparations was standardized by the fibroblast 
FFU  in  the  virus  stocks.  A-MuLV in  combination with  most of the  helper 
viruses efficiently  transformed lymphoid cells. Colonies arising in these cultures 
could routinely be  established as  continuous cell  lines.  Plating efficiency in 
most cases was 80-90%  (data not shown). 
Cultures infected with A-MuLV(E-MuLV) and A-MuLV(G-MuLV) had very 
few macroscopic foci (Table VII). In more than 200 A-MuLV(E-MuLV) infected ABELSON  VIRUS 
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FIG.  1.  Recovery of A-MuLV from mice.  Extracts of bone (b), spleen (s), and thymus (t) 
from mice injected with A-MuLV(M-MuLV-1) or A-MuLV(G-MuLV) were assayed for both 
components of A-MuLV in vitro. Lymph node tumors (n.t.) from terminal animals injected 
with A-MuLV(M-MuLV-1)  were  also  examined.  •  (A-MuLV) indicates FFU  and  []  (M- 
MuLV) indicates PFU recovered in the various tissues from A-MuLV(M-MuLV-1)-injected 
mice.  For mice injected with A-MuLV(G-MuLV), results are shown in one column (A/G) 
although all three tissues were assayed separately. 
cultures, three foci were observed. None of these grew independently in liquid 
culture.  One macroscopic focus has been  noted in a  culture infected with A- 
MuLV(G-MuLV).  The  cells  in  this  focus  did  grow  independently and  were 
established as a  cell line.  The cells appeared to be similar to other A-MuLV 
transformed lymphoid cells with respect to growth and morphologic properties. 
The cells did not produce infectious virus, but did contain the A-MuLV genome 
which could be rescued by superinfection with M-MuLV (data not shown). 
To further investigate the transformation potential of A-MuLV stocks, both 
A-MuLV(E-MuLV) and A-MuLV(G-MuLV) were used to infect mass cultures of 
bone marrow cells. In this transformation test, virus is mixed with bone marrow 
cells in liquid culture and the cells are incubated in the presence of input virus 
and any virus arising by subsequent rounds of replication.  Under conditions 
where an equivalent dose of A-MuLV(M-MuLV-1) transformed 95-100%  of the 
cultures,  no transformation was observed in cultures infected with either A- 
MuLV(E-MuLV) or A-MuLV(G-MuLV). 
The  ratio  of helper  virus  to  fibroblast focus-forming virus  in  different A- 
MuLV stocks varies.  However, the amount of helper virus in A-MuLV stocks 
does not appear to influence the transformation potential of the virus (Table 
VI).  Addition of a  competent helper virus such as  M-MuLV-1 to A-MuLV(G- NAOMI  ROSENBERG  AND  DAVID  BALTIMORE 
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Lymphoid foci/10  ~ fibro-  Lymphoid foci 
PFU  blast FFU  NIH/Swiss mar- 
Virus stock  FFU  row/Lymphoid  OncogeniCin  vivo 
foci BALB/c mar-  NIH/Swiss  BALB/c 
row 
ANN-I(M-MuLV-1)  6  92  48  1.7  Yes 
ANN-I(M-MuLV-2)  5  28  26  1.0  Yes 
ANN-1 (F-MuLV-N)  3  20  0.25  200  Yes 
5H(M-MuLV-2)  3  148  88  1.6  Yes 
5H(F-MuLV-B)  0.5  8  103  0.006  Yes 
ANN-I(G-MuLV)  0.7  <0.01  ND*  No 
ANN-I(E-MuLV)  1.5  <0.02  ND  ND 
NIH/Swiss or BALB/c mouse bone marrow was infected with A-MuLV in vitro and plated in the 
standard lymphoid cell transformation  assay.  Foci were scored 12 days postinfection. The A- 
MuLV stocks are described by the nonproducer cell from which they were derived  and,  in 
parenthesis,  the helper virus used for rescue. 
* ND, not done. 
MuLV) virus at the time of infection did not overcome its inability in transfor- 
mation (data not shown). 
As has been observed for fibroblast cells,  N-tropic A-MuLV stocks preferen- 
tially transform lymphoid cells from Fv-1  "~n mice while B-tropic A-MuLV stocks 
are  much  more efficient on bone marrow cells from Fv-1  b~b mice  (Table VII). 
NB-tropic A-MuLV stocks transform bone marrow cells from both types of mice 
at high efficiency. 
Results obtained in a  different experimental system (28) have suggested that 
Fv-l-mediated restriction does not operate in lymphoid cells. The low transfor- 
mation  frequencies  obtained  with  N-  and  B-tropic  A-MuLV  stocks  on  bone 
marrow cells of inappropriate Fv-1 genotype suggest that lymphoid cell trans- 
formation is subject to the effect of the Fv-1 gene. 
Rescue  of A-MuLV from  Nonproducer Cells.  Lymphoid  nonproducer cell 
lines  were  isolated  by removing  single  foci  from  agarose  culture  plates  and 
adapting  the  cells to  growth  in  liquid  medium.  Nonproducer cell  lines  were 
identified by the lack of reverse transcriptase-containing virus particles in the 
culture  fluid.  Two  nonproducer  cell  cultures,  BR48  and  2M,  were  readily 
superinfected with M-MuLV-2  (Table VIII). After addition of the helper virus, 
infection and release of both helper and focus-forming virus occurred within 12- 
15 h. Superinfected cultures could then be maintained as stable virus-producing 
cell lines. 
Initial attempts to make virus-producing cultures of BR48 cells by using G- 
MuLV  as  a  helper  were  unsuccessful  (Table  VIII).  A  standard  fibroblast 
nonproducer rescue protocol was employed, growing the superinfected cells for 
1.5-2 wk before assaying virus.  More careful study revealed that G-MuLV did 
not form a stable association with lymphoid nonproducer cells. Aider superinfec- 
tion  with  G-MuLV,  virus  production  of both  helper  and  focus-forming virus 
increased for the first 48-h and then declined (Fig. 2). In cultures superinfected 
with  M-MuLV-2,  virus  production  continued in  a  stable  fashion.  After virus 1136  ABELSON  VIRUS 
TABLE VIII 
Superinfection  of A-MuL V Transformed  Nonproducer Cells 
Nonproducer  Helper virus 
Virus Replication 
PFU  FFU 
BR48(Fv-1  ~j~)  M-MuLV-2  1  ×  l0  s  8  x  10  4 
F-MuLV-N  1  x  10 3  2  x  10  2 
G-MuLV-1  9  2 
E-MuLV  0  0 
2M(Fv-1  b/b)  M-MuLV-2  2  x  105  7  ×  104 
F-MuLV-B  1.5  x  108  5  x  105 
C57B1/KaB  0  ND* 
Lymphoid nonproducer  cell  lines  were  infected with  helper  viruses at  an 
raoi of 0.5. After a  2-h adsorption period, cells were maintained as exponen- 
tially  growing cultures  for  10-14  days at  which time  fresh  culture  fluids 
were examined for the presence of PFU and FFU.  Viruses produced by 2M 
cells were assayed on BALB/3T3 cells. Viruses produced by BR48 cells were 
assayed on NIH/3T3 cells. 
* ND, not done. 
production  had  ceased  in  BR48(G-MuLV)  cultures,  the  population  could  be 
reinfected  with  G-MuLV  or  M-MuLV-2  suggesting  that  the  culture  has  lost 
some if not all virus expression from the initial superinfection. 
BR48 cells, an Fv-1  njn cell line,  could be stably superinfected by F-MuLV-N 
but  not  by  E-MuLV  (N-tropic).  2M,  an  Fv-1  bib  cell  line,  could  be  easily 
superinfected by both M-MuLV-2 and F-MuLV-B but not by the B-tropic C57B1/ 
KaB virus (Table VIII).  G-MuLV,  however, did infect a  T-cell lymphoma cell 
line,  L691-6,  and  replicated  nearly  as efficiently as  M-MuLV-2  in these cells 
(Fig.  3). 
Discussion 
These  studies  have  shown  that  A-MuLV  oncogenesis  and  lymphoid  cell 
transformation  is dependent  on which helper  virus rescued and  accompanies 
the defective A-MuLV. Three MuLVs that readily caused lymphomas on their 
own acted as efficient helpers to produce Abelson disease in vivo and lymphoid 
cell transformation  in vitro. Two MuLVs that induced no detectable disease by 
themselves also failed to act as efficient helpers for lymphoid cell transformation 
in vitro and the one that was tested, A-MuLV(G-MuLV), was also inactive in 
vivo.  Neither  component  of  the  A-MuLV(G-MuLV)  stocks  established  an 
infection in the inoculated mice. For fibroblast transformation, however, all five 
helpers were equally active when normalized  to their  PFU content.  There is, 
therefore,  an  important  difference  between  the  requirements  for  A-MuLV 
transformation  of lymphoid cells and of fibroblasts.  Scher  (29) has observed a 
similar distinction in studies with Kirsten sarcoma virus and A-MuLV. 
Transformation  of fibroblasts  by A-MuLV  is  similar  to  transformation  of 
fibroblasts by murine sarcoma viruses in that any MuLV that can replicate on 
its  own  will  act  as  an  effective  helper  (1,  2,  5,  6,  30).  What  then  is  the 
significance  of the  helper  specificity  for  lymphoid  cell  transformation  and 
oncogenesis by A-MuLV? NAOMI  ROSENBERG  AND  DAVID  BALTIMORE  1137 
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FIG.  2.  Replication  of virus  in A-MuLV-transformed lymphoid nonproducer cells.  BR48 
cells  were infected  with  M-MuLV  and G-MuLV at  an moi of  0.1.  Virus  in  the culture  fluids 
was monitored at  intervals  postinfection  by using standard assays. 
Two hypotheses are possible.  One is that the helper is needed for effective 
penetration  of the  A-MuLV  genome  and  that  lymphoid  target  cells  have 
receptors that distinguish the competent helpers from the incompetent ones. 
The other hypothesis is that the helper plays an intracellular role in initiating 
or maintaining the transformation. 
The penetration hypothesis is supported by the inability of an added compe- 
tent helper virus to elicit lymphoid transformation by an incompetent A-MuLV 
stock.  Other explanations  of this  result,  however,  are  possible  and further 
experiments in this area are needed. 
As a test of the penetration hypothesis, we examined the ability of A-MuLV 
transformed nonproducer lymphoid cells to  be  infected by G-MuLV and M- 
MuLV.  Both viruses established infections in the A-MuLV-transformed cells 
therefore, it can be argued, that at least after transformation the cells have 
receptors for both viruses. We cannot test the cells before infection because we 
cannot make a  pure culture of target cells.  A further argument against the 
penetration hypothesis is  the  ability of G-MuLV and M-MuLV pseudotypes 
with vesicular stomatitis virus to infect the A-MuLV-transformed nonproducer 
cells with equal efficiency (P.  Besmer et al., unpublished results). 
The possibility that the "helper" may play a  critical, on-going role in the 
transformation  process  receives  some  support  from  our  studies  of particle 
production by the A-MuLV-transformed  lymphoid cell lines. Some of these lines 
are totally nonproductive but a majority do produce a noninfectious particle (A. 
Shields et al., unpublished results). This particle has a major internal protein 
closely related to that of M-MuLV suggesting that the M-MuLV genome may be 1138 
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FIa.  3.  Replication  of helper virus in L691-6  thymoma cells.  L691-6  cells  were infected 
with M-MuLV-1 and G-MuLV at an moi of 0.1,  Virus in culture fluids was monitored at 
intervals postinfection by using standard assays. 
present  in  most  of the  lymphoid  transformants.  Nucleic  acid  hybridization 
experiments  will be  able to  assess whether  all transformants  might  contain 
some or all of the M-MuLV genome. If the genome is present, it could contribute 
to maintaining the transformed state. This possibility is not without precedent: 
certain murine sarcoma viruses only transform in the presence of a helper virus 
(6, 23). 
The transitory production  of virus after G-MuLV infection of the A-MuLV- 
transformed nonproducer cells (Fig. 2) is not understood. The loss of infectivity 
is so rapid that overgrowth of initially uninfected cells is an unlikely explana- 
tion.  It seems that  G-MuLV,  although  it can initiate  infection,  cannot stably 
maintain  the  infected  state  and  whether  the  G-MuLV  provirus  can  even 
integrate  is not  known.  The  inability  of G-MuLV  to  stably  infect  lymphoid 
nonproducer cells does not reflect an inability of this virus to infect all lymphoid 
cells,  however, because this  virus replicates  nearly  as well as  M-MuLV-2  in 
L691  lymphoma  cells.  This  inability  of G-MuLV  to  maintain  a  productive 
infection of  the A-MuLV-transformed cells may be an explanation of its inability 
to act as an effective helper for A-MuLV transformation. 
The inability of E-MuLV, another inefficient helper, to stably infect lymphoid 
nonproducer  cells supports a  correlation between a  virus'  inability to help A- 
MuLV  transform  lymphoid  cells  and  its  inability  to  stably  associate  with 
lymphoid nonproducer cells. Although the helper efficiency of C57B1/KaB virus 
has not been determined, the virus is fihrotropic and nononcogenic in C57B1/Ka 
mice (22). Thus, the inability of this virus to stably infect 2M cells probably also 
fits this pattern. NAOMI  ROSENBERG  AND  DAVID  BALTIMORE  1139 
The correlation between the oncogenicity of a  replication-competent MuLV 
and its ability to act as an efficient helper is striking. This could suggest that 
the helper virus is providing a  critical leukemogenic function in the transfor- 
mation process. Thus, the data might be reinterpreted by saying that A-MuLV 
is  acting  as  a  helper  for the  replication competent MuLV  in  producing the 
Abelson disease.  The Abelson virus would then function to alter the cellular 
specificity of the leukemogenic virus, e.g. M-MuLV, and allow it to transform 
more immature lymphoid cells than those usually affected by that virus (17). 
These speculations may seem premature but they serve to focus attention on 
the difference between lymphoid cell transformation and fibroblast cell transfor- 
mation. Fibroblast transformation may be a relatively simple process whereby 
a  single  gene  product  establishes  control  of cellular  growth  but  at  present 
leukemia  virus  transformation  has  properties  that  suggest  more  complex 
interactions. 
Summary 
Abelson  murine  leukemia  virus  (A-MuLV)-transformed fibroblast nonpro- 
ducer  cells  were  used  to  prepare  A-MuLV  stocks  containing  a  number  of 
different helper viruses. The oncogenicity of the A-MuLV stocks was tested by 
animal inoculation and their ability to transform normal mouse bone marrow 
cells was measured in vitro. All of the A-MuLV stocks transformed fibroblast 
cells efficiently. However, only A-MuLV stocks prepared with helper viruses 
that are highly oncogenic were efficient in vivo and in vitro in hematopoietic 
cell transformation. In addition,  inefficient helpers did not establish a  stable 
infection in lymphoid nonproducer cells. Thus, helper virus has a more central 
role in lymphoid cell transformation than in fibroblast cell transformation. 
We thank Daniel Clark for excellent technical assistance. 
Received for publication 9 November 1977. 
References 
1.  Huebner, R.  J., J.  W.  Hartley, W.  P.  Rowe, W.  T. Lane, and W.  I.  Capps.  1966. 
Rescue  of the  defective genome of Moloney  sarcoma virus from a  noninfectious 
hamster  tumor and  the  production of pseudotype sarcoma viruses  with  various 
leukemia viruses. Proc. Natl. Acad. Sci.  U.S.A.  56:1164. 
2.  Aaronson,  S.  A.,  J.  L.  Jainchill,  and  G.  J.  Todaro.  1970. Murine sarcoma virus 
transformation of BALB/3T3 cells: Lack of dependence on murine leukemia virus. 
Proc. Natl. Acad. Sci.  U.S.A.  66:1236. 
3.  Peebles,  P.  T.,  B.  I.  Gerwin,  A.  G.  Papageorge, and  S.  G.  Smith.  1975. Murine 
sarcoma virus defectiveness.  Viral polymerase expression in murine and nonmurine 
host cells transformed by S+L- type murine sarcoma virus. Virology.  67:344. 
4.  Peebles,  P.  T.,  B.  I.  Gerwin,  and  E.  M.  Scolnick.  1976. Murine  sarcoma virus 
defectiveness:  serological  detection of only helper virus reverse transcriptase  in 
sarcoma virus rescued from nonmurine S+L- cells. Virology.  70:313. 
5.  Aaronson,  S. A., and W. P. Rowe. 1970. Nonproducer clones ofmurine sarcoma virus 
transformed BALB/3T3 cells. Virology.  42:9. 
6.  Bassin,  R.  H.,  N. Tuttle, and P. J.  Fischinger.  1970. Isolation of murine sarcoma 
virus-transformed mouse  cells  which  are negative for leukemia virus from agar 
suspension  cultures. Int. J. Cancer.  6:95. 1140  ABELSON  VIRUS 
7. Scolnick,  E. M., R. S. Howk, A. Anisowicz, P. T. Peebles, C. D. Scher, and W. P. 
Parks. 1975.  Separation of  sarcoma virus-specific  and leukemia virus-specific  genetic 
sequences of  Moloney sarcoma virus.  Proc. Natl.  Acad. Sci.  U.S.A. 72:4650. 
8. Parks, W. P.,  R. S. Howk, A. Anisowicz, and E. M. Scolnick.  1976.  Deletion  mapping 
of Moloney  type C  virus: polypeptide  and nucleic acid expression in different 
transforming virus isolates.  J. Virol.  18:491. 
9. Martin, G. S. 1970.  Rous sarcoma virus:  a function required for maintenance of  the 
transformed state.  Nature (Lond.). 227:1021. 
10. Vogt, P. K. 1971. Spontaneous segregation of  nontransforming viruses from cloned 
sarcoma viruses.  Virology. 46:939. 
11. Abelson, H. T., and L. S. Rabstein. 1970.  Lymphosarcoma:  virus-induced thymic- 
independent disease in mice. Cancer Res. 30:2213. 
12. Scher, D. C., and R. Siegler. 1975.  Direct transformation of 3T3 cells  by Abelson 
murine leukemia virus. Nature  (Lond.).  253:729. 
13.  Rosenberg,  N.,  D.  Baltimore,  and  C.  D.  Scher.  1975. In  vitro  transformation of 
lymphoid cells by Abelson murine leukemia virus. Proc. Natl. Acad.  Sci.  U.S.A. 
72:1932. 
14.  Rosenberg, N.,  and D. Baltimore. 1976. A quantitative assay for transformation of 
bone marrow cells by Abelson murine leukemia virus. J. Exp. Med.  143:1453. 
15.  Arnstein,  P., J.  L.  Riggs, L.  S.  Oshiro,  R. J.  Huebner,  and E. H. Lennette.  1976. 
Induction  of lymphoma and  associated  xenotropic type C  virus in  C57L mice by 
whole body irradiation. J. Natl. Cancer Inst. 57:1085. 
16.  Baltimore, D., A. E. Silverstone, P. C. Kung, T. A. Harrison, and R. P. MeCaffrey. 
1977. Specialized DNA polymerases in lymphoid cells. Cold Spring Harbor Syrup. 
Quant. Biol.  41:63. 
17.  Silverstone, A.  E.,  N.  Rosenberg,  V.  L.  Sato,  M.  P.  Scheid,  E. A.  Boyse, and D. 
Baltimore. 1978. Correlating terminal deoxynucleotidyl transferase and cell surface 
markers in the pathway of lymphocyte ontogeny. In Control of Cell Proliferation. 
Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. In press. 
18.  Fan, H., and M. Paskind.  1974. Measurement of the sequence complexity of cloned 
Moloney murine leukemia virus 60 to 70S RNA: evidence for a haploid genome. J. 
ViroI.  14:42. 
19.  Hartley, J.  W.,  W.  P.  Rowe,  W.  I. Capps,  and  R.  J.  Huebner.  1969. Isolation of 
naturally occurring viruses of the murine leukemia virus group in tissue culture. J. 
Virol.  3:126. 
20.  Jolicoeur, P., and D. Baltimore. 1975. The effect of the Fv-1 locus on the titration of 
murine leukemia viruses. J. Virol.  16:1593. 
21.  Rowe,  W.  P.,  W.  E.  Pugh,  and J.  W.  Hartley.  1970. Plaque  assay techniques for 
murine leukemia viruses. Virology.  42:1136. 
22.  Decleve,  A.,  M.  Lieberman,  J.  N.  Ihle,  and  H.  S.  Kaplan.  1976. Biological  and 
serological  characterization  of radiation  leukemia  virus.  Proc.  Natl.  Acad.  Sci. 
U.S.A.  73:4675. 
23.  Bassin,  R.  H.,  N.  Tuttle,  and  P.  J.  Fischinger.  1971. Rapid  cell  culture  assay 
technique for murine leukemia viruses. Nature  (Lond.).  269:564. 
24.  Lowry,  O.  H.,  N.  J.  Rosebrough,  A.  L.  Farr,  and  R.  J.  Randall.  1951. Protein 
measurement with the folin reagent. J. Biol. Chem.  193:265. 
25.  Hartley, J.  W.,  W.  P.  Rowe,  and R. J.  Huebner.  1970. Host-range restrictions of 
murine leukemia viruses in mouse embryo cell cultures. J. Virot.  5:221. 
26.  Axelrad,  A.  A.,  and R.  A.  Steeves.  1964. Assay for Friend leukemia virus: rapid 
quantification  method based  on enumeration  of macroscopic spleen  foci in  mice. 
Virology.  24:513. NAOMI  ROSENBERG  AND  DAVID  BALTIMORE  1141 
27.  Wright, B. S., P. A. O'Brien, G. D. Shibley, S. A. Mayyasi, and J. Lasfargues. 1967. 
Infection of an established mouse bone marrow cell lines (JLSV9) with Rauscher and 
Moloney leukemia viruses. J. Natl. Cancer Inst.  27:1672. 
28.  Datta, S. K., C. J. M. Melief,  and R. S. Schwartz. 1975. Lymphocytes and leukemia 
viruses: tropism and transtropism of murine leukemia virus. J. Natl. Cancer Inst. 
55:425. 
29.  Scher, C. D. 1978. Effect of pseudotype on Abelson virus and Kirsten sarcoma virus 
induced leukemia. J. Exp. Med. 147:1044. 
30.  Peebles,  P. T.,  R.  H.  Bassin,  D. L.  Haapala, L.  A. Phillips,  S.  Nomura, and P. J. 
Fischinger. 1971. Rescue of murine sarcoma virus from a sarcoma-positive leukemia 
negative cell line: requirement for replicating leukemia virus. J.  Virol.  8:690. 